The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis
Abstract
BACKGROUND: Guidelines recommend statins as first-line therapy for dyslipidemia. Monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) is a new lipid-lowering approach. PURPOSE: To assess the efficacy and safety of PCSK9 antibodies in adults with hypercholesterolemia. DATA SOURCES: MEDLINE, PubMed Central, and Google Scholar; conference proceedings; and the ClinicalTrials.gov registry through 4 April 2015. STUDY SELECTION: Phase 2 or 3 randomized, controlled trials (RCTs) comparing treatment using PCSK9 antibodies with no anti-PCSK9 therapy in adults with hypercholesterolemia. DATA EXTRACTION: Two investigators independently extracted data on study characteristics and lipid and clinical outcomes, and rated risk of bias of trials. Prespecified primary end points were all-cause and cardiovascular mortality. DATA SYNTHESIS: Twenty-four RCTs comprising 10 159 patients were included. Compared with no antibody, treatment with PCSK9 antibodies led to marked reductions in low-density lipoprotein cholesterol levels (mean difference, -47.49% [95% CI, -69.64% to -25.35%]; P < 0.001] and other atherogenic lipid fractions, and it reduced all-cause mortality (odds ratio [OR], 0.45 [CI, 0.23 to 0.86]; P = 0.015; heterogeneity P = 0.63; I2 = 0%) and cardiovascular mortality (OR, 0.50 [CI, 0.23 to 1.10]; P = 0.084; heterogeneity P = 0.78; I2 = 0%). The rate of myocardial infarction was significantly reduced with use of PCSK9 antibodies (OR, 0.49 [CI, 0.26 to 0.93]; P = 0.030; heterogeneity P = 0.45; I2 = 0%), and increases in the serum creatine kinase level were reduced (OR, 0.72 [CI, 0.54 to 0.96]; P = 0.026; heterogeneity P = 0.65; I2 = 0%). Serious adverse events did not increase with administration of PCSK9 antibodies. LIMITATION: Results were derived from study-level data rather than patient-level data, and clinical outcome data are rare. CONCLUSION: PCSK9 antibodies seem to be safe and effective for adults with dyslipidemia. PRIMARY FUNDING SOURCE: CRC 1116 Masterswitches in Myocardial Ischemia, German Research Council DFG.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Self-citationCollaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse data
J. Sweeting, M., J. Sutton, A., & C. Lambert, P. (2004) · Statistics in Medicine · doi:10.1002/sim.1761 · Cited by 1,734 · cited 1×
“If there were no outcome events, the software automatically applied a treatment-arm continuity correction approach (16).”
Method
Cited by
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Self-citationRecent Developments in Mendelian Randomization Studies
Zheng, J., Baird, D., Borges, M.-C., Bowden, J., Hemani, G., Haycock, P., Evans, D. M., & Smith, G. D. (2017) · Current Epidemiology Reports · doi:10.1007/s40471-017-0128-6 · Cited by 1,147
A highly durable RNAi therapeutic inhibitor of PCSK9
Fitzgerald, K., White, S., Borodovsky, A., Bettencourt, B. R., Strahs, A., Clausen, V., Wijngaard, P., Horton, J. D., Taubel, J., Brooks, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609243 · Cited by 768
Kopin, L., & Lowenstein, C. J. (2017) · Annals of Internal Medicine · doi:10.7326/aitc201712050 · Cited by 582
Navarese, E. P., Robinson, J. G., Kowalewski, M., Kolodziejczak, M., Andreotti, F., Bliden, K., Tantry, U., Kubica, J., Raggi, P., & Gurbel, P. A. (2018) · JAMA · doi:10.1001/jama.2018.2525 · Cited by 549
Self-citationMacrophage‐mediated cholesterol handling in atherosclerosis
Chistiakov, D. A., Bobryshev, Y. V., & Orekhov, A. N. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12689 · Cited by 510
Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing
Yin, H., Song, C.-Q., Suresh, S., Wu, Q., Walsh, S., Rhym, L. H., Mintzer, E., Bolukbasi, M. F., Zhu, L. J., Kauffman, K., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.4005 · Cited by 499
A Brief Review of Cardiovascular Diseases, Associated Risk Factors and Current Treatment Regimes
Flora, G. D., & Nayak, M. K. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190925163827 · Cited by 476
A Modern Approach to Dyslipidemia
Berberich, A. J., & Hegele, R. A. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab037 · Cited by 469
Ibánez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2017) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2017.11.010 · Cited by 461
Self-citationSoppert, J., Lehrke, M., Marx, N., Jankowski, J., & Noels, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.019 · Cited by 407
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study
Schmidt, A. F., Swerdlow, D. I., Holmes, M. V., Patel, R. S., Fairhurst-Hunter, Z., Lyall, D. M., Hartwig, F. P., Horta, B. L., Hyppönen, E., Power, C., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30396-5 · Cited by 380
2017 EACTS Guidelines on perioperative medication in adult cardiac surgery
Sousa-Uva*, M., Head, S. J., Milojevic, M., Collet, J.-P., Landoni, G., Castella, M., Dunning, J., Gudbjartsson, T., Linker, N. J., Sandoval, E., et al. (2018) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezx314 · Cited by 393
Kazi, D. S., Moran, A. E., Coxson, P. G., Penko, J., Ollendorf, D. A., Pearson, S. D., Tice, J. A., Guzman, D., & Bibbins-Domingo, K. (2016) · JAMA · doi:10.1001/jama.2016.11004 · Cited by 382
Cholesterol Biosynthesis: A Mechanistic Overview
Cerqueira, N. M. F. S. A., Oliveira, E. F., Gesto, D. S., Santos-Martins, D., Moreira, C., Moorthy, H. N., Ramos, M. J., & Fernandes, P. A. (2016) · Biochemistry · doi:10.1021/acs.biochem.6b00342 · Cited by 352
Wadhera, R. K., Steen, D. L., Khan, I., Giugliano, R. P., & Foody, J. M. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.11.010 · Cited by 306
Lipinski, M. J., Benedetto, U., Escarcega, R. O., Biondi-Zoccai, G., Lhermusier, T., Baker, N. C., Torguson, R., Brewer, H. B., & Waksman, R. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv563 · Cited by 256
From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk
Shapiro, M. D., & Fazio, S. (2016) · Circulation Research · doi:10.1161/circresaha.115.306471 · Cited by 217
Karatasakis, A., Danek, B. A., Karacsonyi, J., Rangan, B. V., Roesle, M. K., Knickelbine, T., Miedema, M. D., Khalili, H., Ahmad, Z., Abdullah, S., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006910 · Cited by 215
Mack, S., Coassin, S., Rueedi, R., Yousri, N. A., Seppälä, I., Gieger, C., Schönherr, S., Forer, L., Erhart, G., Marques-Vidal, P., et al. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m076232 · Cited by 186
Lipids and Cerebrovascular Disease: Research and Practice
Yaghi, S., & Elkind, M. S. V. (2015) · Stroke · doi:10.1161/strokeaha.115.011164 · Cited by 176
Targeting PCSK9 to tackle cardiovascular disease
Hummelgaard, S., Vilstrup, J. P., Gustafsen, C., Glerup, S., & Weyer, K. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108480 · Cited by 150
Inhibiting PCSK9 — biology beyond LDL control
Stoekenbroek, R. M., Lambert, G., Cariou, B., & Hovingh, G. K. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0110-5 · Cited by 141
Lipid lowering therapy and circulating PCSK9 concentration
Nozue, T. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17012 · Cited by 127
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
Schmidt, A. F., Carter, J.-P. L., Pearce, L. S., Wilkins, J. T., Overington, J. P., Hingorani, A. D., & Casas, J. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011748.pub3 · Cited by 123
Sahebkar, A., Di Giosia, P., Stamerra, C. A., Grassi, D., Pedone, C., Ferretti, G., Bacchetti, T., Ferri, C., & Giorgini, P. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12905 · Cited by 116
Mark, H. (2017) · doi:10.1016/j.jacc.2017.10.001 · Cited by 107
A systematic review of PCSK9 inhibitors alirocumab and evolocumab
McDonagh, M., Peterson, K., Holzhammer, B., & Fazio, S. (2016) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2016.22.6.641 · Cited by 103
Small molecules as inhibitors of PCSK9: Current status and future challenges
Xu, S., Luo, S., Zhu, Z., & Xu, J. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.11.011 · Cited by 85
Navarese, E. P., Kołodziejczak, M., Kereiakes, D. J., Tantry, U. S., O'Connor, C., & Gurbel, P. A. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2994 · Cited by 77
Self-citationPCSK9: Regulation and Target for Drug Development for Dyslipidemia
Burke, A. C., Dron, J. S., Hegele, R. A., & Huff, M. W. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104944 · Cited by 74
Different hypertension thresholds and cognitive decline: a pooled analysis of three ageing cohorts
Ma, Y., Hua, R., Yang, Z., Zhong, B., Yan, L., & Xie, W. (2021) · BMC Medicine · doi:10.1186/s12916-021-02165-4 · Cited by 64
Hegele, R. A., Gidding, S. S., Ginsberg, H. N., McPherson, R., Raal, F. J., Rader, D. J., Robinson, J. G., & Welty, F. K. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.306442 · Cited by 63
“A meta-analysis of phase 2 and 3 trials found reduced total mortality with alirocumab and evolocumab, in trials ranging from 12 to 78 weeks.(92) Four large, ongoing trials of CVD events and safety are evaluating alirocumab, evolocumab, and bococizumab in high risk patient populations.”
MethodMonami, M., Sesti, G., & Mannucci, E. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13599 · Cited by 58
PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia
Ito, M. K., & Santos, R. D. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.766 · Cited by 59
Li, T., Saldanha, I. J., Jap, J., Smith, B. T., Canner, J., Hutfless, S. M., Branch, V., Carini, S., Chan, W., de Bruijn, B., et al. (2019) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2019.07.005 · Cited by 54
Toth, P. P., Bray, S., Villa, G., Palagashvili, T., Sattar, N., Stroes, E. S. G., & Worth, G. M. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.025551 · Cited by 56
World Heart Federation Cholesterol Roadmap
Murphy, A., Faria-Neto, J. R., Al-Rasadi, K., Blom, D., Catapano, A., Cuevas, A., Lopez-Jimenez, F., Perel, P., Santos, R., Sniderman, A., et al. (2017) · Global Heart · doi:10.1016/j.gheart.2017.03.002 · Cited by 43
Gencer, B., Koskinas, K. C., Räber, L., Karagiannis, A., Nanchen, D., Auer, R., Carballo, D., Carballo, S., Klingenberg, R., Heg, D., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006537 · Cited by 35
Evolocumab: A Review in Hyperlipidemia
Keating, G. M. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-015-0153-0 · Cited by 19
Saldanha, I. J., Schmid, C. H., Lau, J., Dickersin, K., Berlin, J. A., Jap, J., Smith, B. T., Carini, S., Chan, W., De Bruijn, B., et al. (2016) · Systematic Reviews · doi:10.1186/s13643-016-0373-7 · Cited by 15
Zheng, X., Yuan, W., Li, L., Ma, H., Zhu, M., Li, X., & Feng, X. (2025) · European Journal of Medical Research · doi:10.1186/s40001-025-02937-1 · Cited by 9
Reed, S. D., Sutphin, J., Gonzalez, J. M., Wallace, M. J., Stephenson, J. J., Electricwala, B., Bosworth, H. B., & Pagidipati, N. (2025) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.124.011804 · Cited by 4
Metadata
- Authors
- Navarese, E. P., Kołodziejczak, M., Schulze, V., Gurbel, P. A., Tantry, U., Lin, Y., Brockmeyer, M., Kandzari, D. E., Kubica, J. M., D'Agostino, R. B., Kubica, J., Volpe, M., Agewall, S., Kereiakes, D. J., & Kelm, M.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2015-07-07
- Volume
- 163
- Issue
- 1
- Pages
- 40-51
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2046181127
- Cited by
- 404
- References
- 38
- FWCI
- 76.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.